

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 January 2003 (09.01.2003)

PCT

(10) International Publication Number
WO 03/002109 A2

(51) International Patent Classification⁷: **A61K 31/00**

SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(21) International Application Number: **PCT/IB02/03302**

(22) International Filing Date: **28 June 2002 (28.06.2002)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(30) Priority Data:
60/301,405 29 June 2001 (29.06.2001) US
60/301,410 29 June 2001 (29.06.2001) US
60/301,409 29 June 2001 (29.06.2001) US
60/341,273 20 December 2001 (20.12.2001) US

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

(71) Applicant (for all designated States except US): **AB SCI-ENCE [FR/FR]**; 3, avenue Georges V, F-75008 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MOUSSY, Alain [FR/FR]**; 22 bis, passage Dauphine, F-75006 Paris (FR). **KINET, Jean-Pierre [FR/US]**; 2 Hunt Road, Lexington, MA 02173 (US).

(74) Agents: **MARTIN, Jean-Jacques et al.**; Cabinet Regim-beau, 20, rue de Chazelles, F-75847 Paris Cedex 17 (FR).

Published:

— without international search report and to be republished upon receipt of that report

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **USE OF TYROSINE KINASE INHIBITORS FOR TREATING AUTOIMMUNE DISEASES**

(57) Abstract: The present invention relates to a method for treating autoimmune diseases, more particularly selected from the group consisting of multiple sclerosis, ulcerative colitis, Crohn's disease, rheumatoid arthritis and polyarthritis, scleroderma, lupus erythematosus, dermatomyositis, pemphigus, polymyositis, vasculitis, as well as graft- versus host diseases, comprising administering a compound capable of depleting mast cells to a mammal in need of such treatment. Such compounds can be chosen from tyrosine kinase inhibitors and more particularly non-toxic, selective and potent c-kit inhibitors. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

WO 03/002109 A2

Use of tyrosine kinase inhibitors for treating autoimmune diseases

The present invention relates to a method for treating autoimmune diseases, more particularly selected from the group consisting of multiple sclerosis, ulcerative colitis, Crohn's disease, rheumatoid arthritis and polyarthritis, scleroderma, lupus erythematosus, dermatomyositis, pemphigus, polymyositis, vasculitis, as well as graft-versus host diseases, comprising administering a compound capable of depleting mast cells to a mammal in need of such treatment. Such compounds can be chosen from tyrosine kinase inhibitors and more particularly non-toxic, selective and potent c-kit inhibitors. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

Autoimmune diseases arise when immune system cells (lymphocytes, macrophages) become sensitized against the "self". Lymphocytes TH and CTL, B lymphocytes as well as macrophages are usually under control in this system. But, a misdirection of the system toward the body's own tissues may happen for still unexplained triggers. In other words, autoimmune disorders occur when the normal control process is disrupted.

The hypothesis is that lymphocytes recognize at some point an antigen which mimics the "self" and a cascade of activation of different components of the immune system takes place, ultimately leading to tissue destruction. Genetic predisposition has also been postulated to be responsible for autoimmune disorders. Autoimmune diseases can affect connective tissue, but it can also affect the nerves, muscles, endocrine system, and the gastrointestinal system.

According to the American Autoimmune Related Diseases Association (AARDA), autoimmune diseases must be regarded "as a united group of disorders". Indeed, the presence of one autoimmune disease in one patient implies the possibility that a second

or third autoimmune disease may occur in the same individual or in other members of the same family.

As suggested by the AARDA, an effective treatment of autoimmune disease requires the
5 identification and turning off these disease-producing T cells. But as of today, such a cure remain elusive.

Typically, these diseases are treated with corticosteroids and immunosuppressant medications (including cyclophosphamide or azathioprine) to reduce the immune
10 response. In addition, US 6,248,368 describes the use of magnesium to treat autoimmune diseases in association with vitamin B6. Compositions containing purified anti-idiotypic antibodies have also been proposed in US 6,231,856 and compositions containing an antisense oligonucleotides targeted to nucleic acids encoding TNF α are mentioned in US 6,228,642 for treating autoimmune diseases.

15

But, none of the above available treatments are effective and safe for treating autoimmune diseases. In addition, the prolonged use of immunosuppressor drugs lead to adverse side effects and morbidity. Moreover, autoimmunity related disorders require lifetime care and treatment, which is expensive and often lead to the disruption of the
20 lifestyle of patients.

Therefore, the problem is to find alternative solutions to provide a relief and a cure for the numerous patients afflicted with these diseases.

In connection with the present invention, we propose that mast cells are the central players involved in autoimmune diseases. Mast cells (MC) are tissue elements derived from a particular subset of hematopoietic stem cells that express CD34, c-kit and CD13 antigens (Kirshenbaum et al, Blood. 94: 2333-2342, 1999 and Ishizaka et al, Curr Opin Immunol. 5: 937-43, 1993). Immature MC progenitors circulate in the bloodstream and differentiate in tissues. These differentiation and proliferation processes are under the influence of cytokines, one of utmost importance being Stem Cell Factor (SCF), also termed Kit ligand (KL), Steel factor (SL) or Mast Cell Growth Factor (MCGF). SCF receptor is encoded by the protooncogene c-kit, that belongs to type III receptor tyrosine kinase subfamily (Boissan and Arock, J Leukoc Biol. 67: 135-48, 2000). This receptor is also expressed on others hematopoietic or non hematopoietic cells. Ligation of c-kit receptor by SCF induces its dimerization followed by its transphosphorylation, leading to the recruitment and activation of various intracytoplasmic substrates. These activated substrates induce multiple intracellular signaling pathways responsible for cell proliferation and activation (Boissan and Arock, 2000). Mast cells are characterized by their heterogeneity, not only regarding tissue location and structure but also at the functional and histochemical levels (Aldenberg and Enerback., Histochem. J. 26: 587-96, 1994 ; Bradding et al. J Immunol. 155: 297-307, 1995 ; Irani et al, J Immunol. 147: 247-53, 1991 ; Miller et al, Curr Opin Immunol. 1: 637-42, 1989 and Welle et al, J Leukoc Biol. 61: 233-45, 1997).

Activation of the detrimental immune response to the self is postulated here to results or to be further stimulated from the degranulation of mast cells. Among to cytokines secreted by mast cells, IFN γ is of particular interest. Indeed, it has been observed that IFN γ is responsible for major histocompatibility complex (MHC) associated autoimmune diseases; Hooks et al, (1979) New England J.Med., Vol. 301 : 5-8. For

example, higher IFN γ levels were shown to correlate with greater severity of disease in SLE patients.

5 TNF is another cytokine produced by mast cells. More recently, it has been reported that TNF produced by mast cells was involved in the pathogenesis of autoantibody-mediated vasculitis, Watanabe N. et al Blood 1999 Dec 1;94(11):3855-63. In Biedermann T et al, J Exp Med 2000 Nov 20;192(10):1441-52, it is shown that mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through TNF and macrophage inflammatory protein 2 (MIP-2).

10

In addition, mast cells are postulated here to participate in the destruction of tissues by releasing a cocktail of different proteases and mediators categorized into three groups: preformed granule-associated mediators (histamine, proteoglycans, and neutral proteases), lipid-derived mediators (prostaglandins, thromboxanes and leucotrienes), and
15 various cytokines (IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, TNF- α , GM-CSF, MIP-1a, MIP-1b, MIP-2 and IFN- γ). Then, liberation by activated mast cells of mediators (TNF- α , histamine, leucotrienes, prostaglandines etc...) as well as proteases is proposed here i) to induce and activate components of the immunity involved in autoimmune diseases and ii) to participate in the tissue destruction process. The activation of T and B
20 lymphocytes against the self stimulate mast cells, which in turn release the above mentioned factors further activating components of the autoimmune reaction.

To break the formation of this cycle leading to tissue destruction, the present invention proposes to deplete mast cells using compounds that are substantially specific to mast
25 cells. In this regard, tyrosine kinase inhibitors and more particularly c-kit specific kinase inhibitors are proposed to inhibit mast cell proliferation, survival and activation.

A new route for treating autoimmune diseases is provided, which consists of destroying mast cells playing a role in the pathogenesis of these disorders. It has been found that tyrosine kinase inhibitors and more particularly c-kit inhibitors are especially suited to reach this goal.

Description

The present invention relates to a method for treating autoimmune diseases comprising administering a compound capable of depleting mast cells to a mammal in need of such treatment.

Said method for treating autoimmune diseases can comprise administering a tyrosine kinase inhibitor to a mammal in need of such treatment.

Tyrosine kinase inhibitors are selected for example from bis monocyclic, bicyclic or heterocyclic aryl compounds (WO 92/20642), vinylene-azaindole derivatives (WO 94/14808) and 1-cyclopropyl-4-pyridyl-quinolones (US 5,330,992), Styryl compounds (US 5,217,999), styryl-substituted pyridyl compounds (US 5,302,606), seleoindoles and selenides (WO 94/03427), tricyclic polyhydroxylic compounds (WO 92/21660) and benzylphosphonic acid compounds (WO 91/15495), pyrimidine derivatives (US 5,521,184 and WO 99/03854), indolinone derivatives and pyrrol-substituted indolinones (US 5,792,783, EP 934 931, US 5,834,504, US 5,883,116, US 5,883,113, US 5,886,020, WO 96/40116 and WO 00/38519), as well as bis monocyclic, bicyclic aryl and heteroaryl compounds (EP 584 222, US 5,656,643 and WO 92/20642), quinazoline derivatives (EP 602 851, EP 520 722, US 3,772,295 and US 4,343,940) and aryl and heteroaryl quinazoline (US 5,721,237, US 5,714,493, US 5,710,158 and WO 95/15758).


Preferably, said tyrosine kinase inhibitors are unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

In another embodiment, the invention is directed to a method for treating autoimmune diseases comprising administering a c-kit inhibitor to a mammal in need of such treatment.

Preferably, said c-kit inhibitor is a non-toxic, selective and potent c-kit inhibitor. Such inhibitors can be selected from the group consisting of indolinones, pyrimidine derivatives, pyrrolopyrimidine derivatives, quinazoline derivatives, quinoxaline derivatives, pyrazoles derivatives, bis monocyclic, bicyclic or heterocyclic aryl compounds, vinylene-azaindole derivatives and pyridyl-quinolones derivatives, styryl compounds, styryl-substituted pyridyl compounds, seleoindoles, selenides, tricyclic polyhydroxylic compounds and benzylphosphonic acid compounds.

Among preferred compounds, it is of interest to focus on pyrimidine derivatives such as N-phenyl-2-pyrimidine-amine derivatives (US 5,521,184 and WO 99/03854), indolinone derivatives and pyrrol-substituted indolinones (US 5,792,783, EP 934 931, US 5,834,504), US 5,883,116, US 5,883,113, US 5, 886,020, WO 96/40116 and WO 00/38519), as well as bis monocyclic, bicyclic aryl and heteroaryl compounds (EP 584 222, US 5,656,643 and WO 92/20642), quinazoline derivatives (EP 602 851, EP 520 722, US 3,772,295 and US 4,343,940), 4-amino-substituted quinazolines (US 3,470,182), 4-thienyl-2-(1H)-quinazolones, 6,7-dialkoxyquinazolines (US 3,800,039), aryl and heteroaryl quinazoline (US 5,721,237, US 5,714,493, US 5,710,158 and WO 95/15758), 4-anilinoquinazoline compounds (US 4,464,375), and 4-thienyl-2-(1H)-quinazolones (US 3,551,427).


So, preferably, the invention relates to a method for treating autoimmune diseases comprising administering a non toxic, potent and selective c-kit inhibitor is a pyrimidine derivatives, more particularly N-phenyl-2-pyrimidine-amine derivatives of formula I :



- 5 wherein the R1, R2, R3, R13 to R17 groups have the meanings depicted in EP 564 409 B1, incorporated herein in the description.

Preferably, the N-phenyl-2-pyrimidine-amine derivative is selected from the compounds corresponding to formula II :

10




Wherein R1, R2 and R3 are independently chosen from H, F, Cl, Br, I, a C1-C5 alkyl or a cyclic or heterocyclic group, especially a pyridyl group;

- 15 R4, R5 and R6 are independently chosen from H, F, Cl, Br, I, a C1-C5 alkyl, especially a methyl group;


and R7 is a phenyl group bearing at least one substituent, which in turn possesses at least one basic site, such as an amino function.

Preferably, R7 is the following group :




Among these compounds, the preferred are defined as follows :

- 5 R1 is a heterocyclic group, especially a pyridyl group,
 R2 and R3 are H,
 R4 is a C1-C3 alkyl, especially a methyl group,
 R5 and R6 are H,
 and R7 is a phenyl group bearing at least one substituent, which in turn possesses at least
 10 one
 basic site, such as an amino function, for example the group :



- Therefore, in a preferred embodiment, the invention relates to a method for treating
 15 autoimmune diseases comprising the administration of an effective amount of the
 compound known in the art as CGP57148B :

4-(4-méthylpipérazine-1-ylméthyl)-N-[4-méthyl-3-(4-pyridine-3-yl)pyrimidine-2
 ylamino)phényl]-benzamide corresponding to the following formula :



The preparation of this compound is described in example 21 of EP 564 409 and the β -form, which is particularly useful is described in WO 99/03854.

5 Alternatively, the c-kit inhibitor can be selected from :

- indolinone derivatives, more particularly pyrrol-substituted indolinones,
- monocyclic, bicyclic aryl and heteroaryl compounds, quinazoline derivatives,
- and quinaxolines, such as 2-phényl-quinaxoline derivatives, for example 2-phenyl-6,7-dimethoxy quinaxoline.

10

In a preferred aspect, the invention contemplated the method mentioned above, wherein said c-kit inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

15 The following autoimmune diseases as referred herein are contemplated by the present invention :

- multiple sclerosis, psoriasis, intestine inflammatory disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis and polyarthritis, local and systemic scleroderma, systemic lupus erythematosus, discoid lupus erythematosus, cutaneous
- 20 lupus, dermatomyositis, polymyositis, Sjogren's syndrome, nodular panarteritis, autoimmune enteropathy, as well as proliferative glomerulonephritis.
- graft-versus-host disease or graft rejection in any organ transplantation including kidney, pancreas, liver, heart, lung, and bone marrow.
- Other autoimmune diseases embraced by the invention active chronic hepatitis and
- 25 chronic fatigue syndrome.
- subepidermal blistering disorders such as pemphigus.
- Vasculitis.

In a preferred embodiment, the method of the invention is applicable to prevent tissue damage and reduce pain in rheumatoid arthritis and in Lupus erythematosus. Lupus is an autoimmune disease in which the immune system becomes overactive and produces
5 antibodies that attack tissues in the body, producing inflammation, redness, pain, and swelling. Lupus is a serious health problem that affects mainly young women.

In another preferred embodiment, the method of the invention is applicable to the treatment of multiple sclerosis. Indeed, a significant increase in the number of mast cells
10 has been observed in the border zones of the plaques. This embodiment is the subject-matter of US 60/601,409 filed by the applicant on June 29, 2001.

In another preferred embodiment, the method of the invention is applicable to the treatment of psoriasis. About 2% of adults have psoriasis, which results in skin growing
15 faster and thicker due to an abnormal immune reaction against some component of the skin.

In another preferred embodiment, the method of the invention is applicable to the treatment of rheumatoid arthritis and polyarthritis, for which the applicant filed US
20 60/301,410 on June 29, 2001.

In another preferred embodiment, the method of the invention is applicable to the treatment of ulcerative colitis and Crohn's disease, for which the applicant filed US
60/301,405 on June 29, 2001.

In another preferred embodiment, the method of the invention is applicable to the treatment of Dermatomyositis, which is an acquired muscle disease also called inflammatory myopathies. Dermatomyositis is characterized by a rash accompanying, or more often, preceding muscle weakness.

5

In still another preferred embodiment, the method of the invention is applicable to the treatment of subepidermal blistering disorders. The following subepidermal blistering disorders as referred herein are contemplated by the present invention : aphthous ulcers, and several bullous diseases such as pemphigus, bullous pemphigoid and cicatricial pemphigoid.

10

The method as depicted above is particularly useful for treating Pemphigus vulgaris. In this disorder, lesions occur in the mouth, as well as on the chest, scalp, periumbilical, and various other areas of the skin. Oral lesions have also been observed. This form of the disease can involve the oropharynx and other mucosal surfaces ; this is why the invention contemplates compositions for topical as well as oral administration suitable to reach the particular tissues indicated above.

15

The method as depicted above is particularly useful for treating Pemphigus vegetans, in which vegetating lesions and pustules form. Pustules are the result of a super-infection at the edges of the broken bullae. In this regard, antibiotics can be used concomitant with tyrosine kinase inhibitors, for example with c-kit inhibitors. Among antibiotics, the preferred ones are selected from dapsone, azathioprine, erythromycin, propionylerythromycin, neomycin, gentomycin, tobramycin, and mechlerycline. At last, hyperkeratosis, pseudoepitheliomatous hyperplasia, and papillomatosis have also been observed in this disease and will be treated accordingly.

20

25

The method as depicted above is also particularly useful for treating Pemphigus foliaceus, which symptoms include crusting, scales, erosion, and excoriations.

- 5 The method as depicted above is also particularly useful for treating Pemphigus erythematosus. Here, lesions are lupus-like butterfly rash as well as bullous and seborrheic dermatitis-like lesions.

10 The method as depicted above is also particularly useful for treating Vasculitis which involves inflammation in blood vessels of various sizes from the aorta to the smallest blood vessels in the skin. This group of diseases encompasses Giant Cell Arteritis, Polymyalgia Rheumatica, Wegener's Granulomatosis, Polyarteritis Nodosa, Hypersensitivity Vasculitis, Rheumatoid Vasculitis, Microscopic Polyangiitis, Buerger's Disease Kawasaki's Disease as well as Vasculitis caused by infection or allergy.

15

Preferably, the methods as depicted above are applicable for preventing and/or treating autoimmune diseases in human.

20 In a further embodiment, c-kit inhibitors as mentioned above are inhibitors of activated c-kit. In frame with the invention, the expression "activated c-kit" means a constitutively activated-mutant c-kit including at least one mutation selected from point mutations, deletions, insertions, but also modifications and alterations of the natural c-kit sequence (SEQ ID N°1). Such mutations, deletions, insertions, modifications and alterations can occur in the transphosphorylase domain, in the juxtamembrane domain as well as in any
25 domain directly or indirectly responsible for c-kit activity. The expression "activated c-kit" also means herein SCF-activated c-kit. Preferred and optimal SCF concentrations for activating c-kit are comprised between $5 \cdot 10^{-7}$ M and $5 \cdot 10^{-6}$ M, preferably around

2.10⁻⁶ M. In a preferred embodiment, the activated-mutant c-kit in step a) has at least one mutation proximal to Y823, more particularly between amino acids 800 to 850 of SEQ ID No1 involved in c-kit autophosphorylation, notably the D816V, D816Y, D816F and D820G mutants. In another preferred embodiment, the activated-mutant c-kit in step a) has a deletion in the juxtamembrane domain of c-kit. Such a deletion is for example between codon 573 and 579 called c-kit d(573-579). The point mutation V559G proximal to the juxtamembrane domain c-kit is also of interest.

In this regard, the invention contemplates a method for treating autoimmune diseases comprising administering to a mammal in need of such treatment a compound that is a selective, potent and non toxic inhibitor of activated c-kit obtainable by a screening method which comprises :

- a) bringing into contact (i) activated c-kit and (ii) at least one compound to be tested; under conditions allowing the components (i) and (ii) to form a complex,
- b) selecting compounds that inhibit activated c-kit,
- c) testing and selecting a subset of compounds identified in step b), which are unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

This screening method can further comprise the step consisting of testing and selecting a subset of compounds identified in step b) that are inhibitors of mutant activated c-kit (for example in the transphosphorylase domain), which are also capable of inhibiting SCF-activated c-kit wild.

Alternatively, in step a) activated c-kit is SCF-activated c-kit wild.

A best mode for practicing this method consists of testing putative inhibitors at a concentration above 10 μ M in step a). Relevant concentrations are for example 10, 15, 20, 25, 30, 35 or 40 μ M.

In step c), IL-3 is preferably present in the culture media of IL-3 dependent cells at a concentration comprised between 0.5 and 10 ng/ml, preferably between 1 to 5 ng/ml.

Examples of IL-3 dependent cells include but are not limited to :

- 5 - cell lines naturally expressing and depending on c-kit for growth and survival. Among such cells, human mast cell lines can be established using the following procedures : normal human mast cells can be infected by retroviral vectors containing sequences coding for a mutant c-kit comprising the c-kit signal peptide and a TAG sequence allowing to differentiate mutant c-kits from c-kit wild expressed in hematopoietic cells by means of antibodies.
- 10

This technique is advantageous because it does not induce cellular mortality and the genetic transfer is stable and gives satisfactory yields (around 20 %). Pure normal human mast cells can be routinely obtained by culturing precursor cells originating from blood obtained from human umbilical vein. In this regard, heparinated blood from umbilical

15 vein is centrifuged on a Ficoll gradient so as to isolate mononucleated cells from other blood components. CD34+ precursor cells are then purified from the isolated cells mentioned above using the immunomagnetic selection system MACS (Miltenyi biotech). CD34+ cells are then cultured at 37°C in 5 % CO₂ atmosphere at a concentration of 10⁵ cells per ml in the medium MCCM (α-MEM supplemented with L-glutamine, penicillin,

20 streptomycin, 5 10⁻⁵ M β-mercaptoethanol, 20 % veal foetal serum, 1 % bovine albumin serum and 100 ng/ml recombinant human SCF. The medium is changed every 5 to 7 days. The percentage of mast cells present in the culture is assessed each week, using May-Grünwal Giemsa or Toluidine blue coloration. Anti-tryptase antibodies can also be used to detect mast cells in culture. After 10 weeks of culture, a pure cellular population

25 of mast cells (> 98 %) is obtained.

It is possible using standard procedures to prepare vectors expressing c-kit for transfecting the cell lines established as mentioned above. The cDNA of human c-kit has been described in Yarden et al., (1987) EMBO J.6 (11), 3341-3351. The coding part of c-kit (3000 bp) can be amplified by PCR and cloned, using the following oligonucleotides :

- 5'AAGAAGAGATGGTACCTCGAGGGGTGACCC3' (SEQ ID No2) sens
- 5'CTGCTTCGCGGCCGCGTTAACTCTTCTCAACCA3' (SEQ ID No3) antisens

The PCR products, digested with NotI and XhoI, has been inserted using T4 ligase in the pFlag-CMV vector (SIGMA), which vector is digested with NotI and XhoI and dephosphorylated using CIP (Biolabs). The pFlag-CMV-c-kit is used to transform bacterial clone XL1-blue. The transformation of clones is verified using the following primers :

- 5'AGCTCGTTTAGTGAACCGTC3' (SEQ ID No4) sens,
- 15 - 5'GTCAGACAAAATGATGCAAC3' (SEQ ID No5) antisens.

Directed mutagenesis is performed using relevant cassettes is performed with routine and common procedure known in the art..

The vector Migr-I (ABC) can be used as a basis for constructing retroviral vectors used for transfecting mature mast cells. This vector is advantageous because it contains the sequence coding for GFP at the 3' and of an IRES. These features allow to select cells infected by the retrovirus using direct analysis with a fluorocytometer. As mentioned above, the N-terminal sequence of c-kit c-DNA can be modified so as to introduce a Flag sequence that will be useful to discriminating heterogeneous from endogenous c-kit.

25 Other IL-3 dependent cell lines that can be used include but are not limited to:

- BaF3 mouse cells expressing wild-type or mutated form of c-kit (in the juxtamembrane and in the catalytic sites) are described in Kitayama et al, (1996), Blood 88, 995-1004 and Tsujimura et al, (1999), Blood 93, 1319-1329.
- IC-2 mouse cells expressing either c-kit^{WT} or c-kit^{D814Y} are presented in Piao et al, 5 (1996), Proc. Natl. Acad. Sci. USA 93, 14665-14669.

IL-3 independent cell lines are :

- HMC-1, a factor-independent cell line derived from a patient with mast cell leukemia, expresses a juxtamembrane mutant c-kit polypeptide that has constitutive kinase activity 10 (Furitsu T et al, J Clin Invest. 1993;92:1736-1744 ; Butterfield et al, Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res. 1988;12:345-355 and Nagata et al, Proc Natl Acad Sci U S A. 1995;92:10560-10564).
- P815 cell line (mastocytoma naturally expressing c-kit mutation at the 814 position) has been described in Tsujimura et al, (1994), Blood 83, 2619-2626.

15

The extent to which component (ii) inhibits activated c-kit can be measured *in vitro* or *in vivo*. In case it is measured *in vivo*, cell lines expressing an activated-mutant c-kit, which has at least one mutation proximal to Y823, more particularly between amino acids 800 20 to 850 of SEQ ID No1 involved in c-kit autophosphorylation, notably the D816V, D816Y, D816F and D820G mutants, are preferred.

Example of cell lines expressing an activated-mutant c-kit are as mentioned.

In another preferred embodiment, the method further comprises the step consisting of 25 testing and selecting compounds capable of inhibiting c-kit wild at concentration below 1 μ M. This can be measured *in vitro* or *in vivo*.

Therefore, compounds are identified and selected according to the method described above are potent, selective and non-toxic c-kit wild inhibitors.

Alternatively, the screening method as defined above can be practiced *in vitro*. In this regard, the inhibition of mutant-activated c-kit and/or c-kit wild can be measured using standard biochemical techniques such as immunoprecipitation and western blot. Preferably, the amount of c-kit phosphorylation is measured.

In a still further embodiment, the invention contemplates a method for treating autoimmune diseases as depicted above wherein the screening comprises :

- a) performing a proliferation assay with cells expressing a mutant c-kit (for example in the transphosphorylase domain), which mutant is a permanent activated c-kit, with a plurality of test compounds to identify a subset of candidate compounds targeting activated c-kit, each having an $IC_{50} < 10 \mu M$, by measuring the extent of cell death,
- b) performing a proliferation assay with cells expressing c-kit wild said subset of candidate compounds identified in step (a), said cells being IL-3 dependent cells cultured in presence of IL-3, to identify a subset of candidate compounds targeting specifically c-kit,
- c) performing a proliferation assay with cells expressing c-kit, with the subset of compounds identified in step b) and selecting a subset of candidate compounds targeting c-kit wild, each having an $IC_{50} < 10 \mu M$, preferably an $IC_{50} < 1 \mu M$, by measuring the extent of cell death.

Here, the extent of cell death can be measured by 3H thymidine incorporation, the trypan blue exclusion method or flow cytometry with propidium iodide. These are common techniques routinely practiced in the art.

The method according to the invention includes preventing, delaying the onset and/or treating autoimmune diseases in mammals, especially in human.

- 5 In the method defined above, any compound capable of depleting mast cells can be used. Such compounds can belong to, as explicated above, tyrosine kinase inhibitors, such as c-kit inhibitors, but are not limited to any particular family so long as said compound shows capabilities to deplete mast cells. Depletion of mast cells can be evaluated using for example one of the mast cell lines depicted above using routine procedure.
- 10 Best compounds are compounds exhibiting the greatest selectivity. Control cell lines include other hematopoietic cells that are not mast cells or related cells or cell lines. These control cell lines include SCF independent expanded human CD34+ normal cells. These control cells also include but are not limited to the human T lymphocyte Jurkat cell line (ATCC N° TIB-152 and mutant cell lines derived thereof),
- 15 the human B lymphocyte Daudi or Raji cell line (ATCC N° CCL-213 and CCL-86 respectively), the human monocytic U 937 cell line (ATCC N° CRL-1593.2) and the human HL-60 cell line (ATCC N° CCL-240) and mutant cell lines derived thereof CRL-2258 and CRL-2392).
- 20 Such compounds can be identified using with a method for identifying compounds capable of depleting mast cells, said compound being non-toxic for cell types other than mast cells, comprising the step consisting of :
- a) culturing mast cells in vitro in a culture medium suitable for mast cells,
 - b) adding to said culture medium at least one compound to be tested and incubating said
 - 25 cells for a prolonged period of time,
 - c) selecting compounds that promote mast cells death,
 - d) identifying a subset of compounds selected in step c) that are unable to promote death of cells selected from the above mentioned control cell lines.

Therefore, the invention embraces the use of the compounds defined above to manufacture a medicament for treating autoimmune diseases such as multiple sclerosis, psoriasis, intestine inflammatory disease, ulcerative colitis, Crohn's disease, rheumatoid
5 arthritis and polyarthritis, dermatomyositis, polymyositis, Sjogren's syndrome, nodular panarteritis, autoimmune enteropathy, proliferative glomerulonephritis, active chronic hepatitis, as well as graft-versus host diseases.

The invention is also directed to the use of the compounds defined above to manufacture
10 a medicament for treating a T cell-mediated disease, preferably one selected from the group consisting of myasthenia gravis, scleroderma, graft-versus-host disease, graft rejection, Graves disease, Addison's disease, autoimmune uveoretinitis, autoimmune thyroiditis, systemic lupus erythematosus, discoid lupus erythematosus, cutaneous lupus, local and systemic scleroderma, psoriasis, dermatomyositis, and primary biliary
15 cirrhosis.

More particularly, the invention concerns the use of the compounds defined above to manufacture a medicament for treating and/or preventing tissue damage and to reduce pain in Lupus erythematosus.

20

Compounds as defined above can also be used to manufacture a medicament to prevent or treat graft-versus-host disease or graft rejection in any organ transplantation including kidney, pancreas, liver, heart, lung and bone marrow.

Compounds as defined above can also be used to manufacture a medicament to prevent or treat polymyositis, Sjogren's syndrome, nodular panarteritis, autoimmune enteropathy, proliferative glomerulonephritis, active chronic hepatitis and chronic fatigue syndrome.

Compounds as defined above to manufacture a medicament for treating subepidermal blistering disorders such as aphthous ulcers, and several bullous diseases such as pemphigus, bullous pemphigoid and cicatricial pemphigoid.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, Pa.).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

More particularly, the invention relates to a pharmaceutical composition intended for oral or topical administration.

Regarding topical administration, the compositions according to the invention may be presented in the form of a gel, paste, ointment, cream, lotion, liquid suspension aqueous, aqueous-alcoholic or, oily solutions, or dispersions of the lotion or serum type, or anhydrous or lipophilic gels, or emulsions of liquid or semi-solid consistency of the milk
5 type, obtained by dispersing a fatty phase in an aqueous phase or vice versa, or of suspensions or emulsions of soft, semi-solid consistency of the cream or gel type, or alternatively of microemulsions, of microcapsules, of microparticles or of vesicular dispersions to the ionic and/or nonionic type. These compositions are prepared according to standard methods.

10

The composition according to the invention comprises any ingredient commonly used in dermatology and cosmetic. It may comprise at least one ingredient selected from hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, emollients, viscosity enhancing polymers, humectants, surfactants,
15 preservatives, antioxidants, solvents, and fillers, antioxidants, solvents, perfumes, fillers, screening agents, bactericides, odor absorbers and coloring matter.

As oils which can be used in the invention, mineral oils (liquid paraffin), vegetable oils (liquid fraction of shea butter, sunflower oil), animal oils, synthetic oils, silicone oils
20 (cyclomethicone) and fluorinated oils may be mentioned. Fatty alcohols, fatty acids (stearic acid) and waxes (paraffin, carnauba, beeswax) may also be used as fatty substances.

As emulsifiers which can be used in the invention, glycerol stearate, polysorbate 60 and
25 the PEG-6/PEG-32/glycol stearate mixture are contemplated.

As hydrophilic gelling agents, carboxyvinyl polymers (carbomer), acrylic copolymers such as acrylate/alkylacrylate copolymers, polyacrylamides, polysaccharides such as hydroxypropylcellulose, clays and natural gums may be mentioned, and as lipophilic

gelling agents, modified clays such as bentones, metal salts of fatty acids such as aluminum stearates and hydrophobic silica, or alternatively ethylcellulose and polyethylene may be mentioned.

- 5 As hydrophilic active agents, proteins or protein hydrolysates, amino acids, polyols, urea, allantoin, sugars and sugar derivatives, vitamins, starch and plant extracts, in particular those of Aloe vera may be used.

As lipophilic active agents, retinol (vitamin A) and its derivatives, tocopherol (vitamin
10 E) and its derivatives, essential fatty acids, ceramides and essential oils may be used. These agents add extra moisturizing or skin softening features when utilized.

In addition, a surfactant can be included in the composition so as to provide deeper penetration of the compound capable of depleting mast cells, such as a tyrosine kinase
15 inhibitor, preferably a c-kit inhibitor.

Among the contemplated ingredients, the invention embraces penetration enhancing agents selected for example from the group consisting of mineral oil, water, ethanol, triacetin, glycerin and propylene glycol; cohesion agents selected for example from the
20 group consisting of polyisobutylene, polyvinyl acetate and polyvinyl alcohol, and thickening agents.

Chemical methods of enhancing topical absorption of drugs are well known in the art. For example, compounds with penetration enhancing properties include sodium lauryl
25 sulfate (Dugard, P. H. and Sheuplein, R. J., "Effects of Ionic Surfactants on the Permeability of Human Epidermis: An Electrometric Study," J. Invest. Dermatol., V.60, pp. 263-69, 1973), lauryl amine oxide (Johnson et. al., US 4,411,893), azone (Rajadhyaksha, US 4,405,616 and 3,989,816) and decylmethyl sulfoxide (Sekura, D. L.

and Scala, J., "The Percutaneous Absorption of Alkylmethyl Sulfides," Pharmacology of the Skin, Advances In Biology of Skin, (Appleton-Century Craft) V. 12, pp. 257-69, 1972). It has been observed that increasing the polarity of the head group in amphoteric molecules increases their penetration-enhancing properties but at the expense of increasing their skin irritating properties (Cooper, E. R. and Berner, B., "Interaction of Surfactants with Epidermal Tissues: Physiochemical Aspects," Surfactant Science Series, V. 16, Reiger, M. M. ed. (Marcel Dekker, Inc.) pp. 195-210, 1987).

A second class of chemical enhancers are generally referred to as co-solvents. These materials are absorbed topically relatively easily, and, by a variety of mechanisms, achieve permeation enhancement for some drugs. Ethanol (Gale et. al., U.S. Pat. No. 4,615,699 and Campbell et. al., U.S. Pat. Nos. 4,460,372 and 4,379,454), dimethyl sulfoxide (US 3,740,420 and 3,743,727, and US 4,575,515), and glycerine derivatives (US 4,322,433) are a few examples of compounds which have shown an ability to enhance the absorption of various compounds.

Topical composition referred herein are particularly relevant for treating diseases affecting the skin and mucosal membranes. Examples of these disorders include psoriasis, systemic lupus erythematosus, discoid lupus erythematosus, cutaneous lupus, local and systemic scleroderma, and dermatomyositis. This composition comprises a compound capable of depleting mast cells, preferably a tyrosine kinase inhibitor, more particularly a c-kit inhibitor as mentioned above.

Topical composition referred herein are also particularly relevant for treating aphthous ulcers, and several bullous diseases such as pemphigus, bullous pemphigoid and cicatricial pemphigoid since they are affecting especially the skin and mucosal membranes.

As mentioned above, the invention also contemplates a composition suitable for oral administration comprising a compound capable of depleting mast cells, preferably a tyrosine kinase inhibitor, more particularly a c-kit inhibitor for the manufacture of a medicament for the treatment of multiple sclerosis, intestine inflammatory disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis and polyarthritis, myasthenia gravis, polymyositis, graft-versus-host disease, graft rejection, Graves disease, Addison's disease, autoimmune uveoretinitis, autoimmune thyroiditis, primary biliary cirrhosis, Sjogren's syndrome, nodular panarteritis, autoimmune enteropathy, proliferative glomerulonephritis, active chronic hepatitis and chronic fatigue syndrome.

Pharmaceutical compositions suitable for use in the invention include compositions wherein compounds for depleting mast cells, such as tyrosine kinase inhibitors and c-kit inhibitors, are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art. A therapeutically effective dose refers to that amount of active ingredient, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. As mentioned above, a tyrosine kinase inhibitor and more particularly a c-kit inhibitor according to the invention is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

The invention also contemplates a product comprising at least one compound capable of depleting mast cells, such as a tyrosine kinase inhibitors, more particularly a non-toxic,

selective and potent c-kit inhibitor and at least one antibiotic, the preferred ones being selected from cyclophosphamide, methotrexate, dapsone, azathioprine, erythromycin, propionylerythromycin, neomycin, gentomycin, tobramycin, and mechlocycline for simultaneous, separate or sequential use for the treatment of subepidermal blistering disorders, such as pemphigus.

Utility of the invention will further ensue from the detailed description below.

Example 1 : Treatment of subepidermal blistering disorders

Pemphigus affects people across racial and cultural lines. It produces burn-like lesions that will not heal, which results of the loss of intercellular adhesion between the keratinocytes leading to bulla (blister) formation (Sharpe, R. J. in Manual of Clinical Problems in Dermatology, Olbricht, Bigby and Arndt eds., Little Brown & Co., Boston, 1992, pp. 56-60). Pemphigus vulgaris and Pemphigus vegetans are characterized by the formation of blisters above the basal layer of the skin. In Pemphigus foliaceus and Pemphigus erythematosus, blisters are observed just below the stratum corneum. For a review, see Ruocco E, et al, Precautions and suggestions for pemphigus patients, Dermatology 2001;203(3):201-7 and Hertl M, Veldman C, Pemphigus - paradigm of autoantibody-mediated autoimmunity, Int J Fertil Womens Med 2001 Jul-Aug;46(4):190-205.

Current treatments of pemphigus includes corticosteroids and immunosuppressive agents such as cyclophosphamide, azathioprine, methotrexate and cyclosporine-A (Lever, J. Am. Acad. Dermatol. 1979, Vol. 1, pp. 2-31). But, the severity of symptoms and the high mortality associated with pemphigus often lead to hospitalization. In addition, clinically significant bone loss occurs in the vast majority of patients exposed to

corticosteroids with a very high risk for vertebral fracture, see Adachi JD, Corticosteroid-induced osteoporosis, *Acta Derm Venereol* 1999 Sep;79(5):351-5.

5 Bullous pemphigoid is more prevalent in elderly patients and include large tense blisters, on erythematous or non-erythematous skin or on urticarial plaques. A mortality rate of 10 to 20 percent is reported for the disease, largely due to side-effects from the use of systemic steroid therapy.

10 Cicatricial Pemphigoid involves primarily the mucous membranes (Baden, L. A., Manual of Clinical Problems in Dermatology, Little, Brown & Co., Boston, 1992, pp. 54). In many cases, this disorder involves desquamative gingivitis and ultimately leads to blindness. Current treatments are as mentioned above and are not satisfactory (Bleicher, supra; Arndt, K. in Fitzpatrick, Eisen, Wolff, Freedberg and Austen, *Dermatology in General Medicine*, 1987, Vol. 1, McGraw-Hill, Inc., New York, pp. 582-584).
15 Antibiotics can also be used in combinaison with high dose corticosteroids.

A common feature of pemphigus, bullous pemphigoid, cicatricial pemphigoid is the role of proteases in their pathogenesis (Grando, Glukhenky, Drannik, Kostromin and Chernyavsky, *Int. J. Tissue React.* 1989, Vol. 11, pp. 195-201). This diseases are
20 classified as being mediated by proteases which affect especially the skin and mucosal membranes. In this regard, some proteinase inhibitors have been proposed in the treatment of pemphigus. Furthermore, in US 5,637,616, systemic administration of N-acetylcysteine is proposed for treating these diseases and in US 5,514,714 the use hypericin or pseudohypericin is described for treating pemphigus.

Still, as of today, none of the above available treatments are effective and safe for treating subepidermal blistering disorders. In addition, the prolonged use of immunosuppressor drugs lead to adverse side effects and morbidity.

- 5 A long time ago, participation of mast cells was suggested by a sequence of pathologic alterations in which there was progressive mast-cell degranulation and late eosinophil infiltration, Wintroub BU et al, Morphologic and functional evidence for release of mast-cell products in bullous pemphigoid, N Engl J Med 1978 Feb 23;298(8):417-21. More recently, a significant alterations in mast cell chymase and protease in different
- 10 bullous diseases has been observed, suggesting mast cell involvement. But, it was thought that this reflected a general inflammation rather than a specific reaction, Kaminska R et al, Mast cells in developing subepidermal bullous diseases: emphasis on tryptase, chymase and protease inhibitors, Acta Derm Venereol 1999 Sep;79(5):351-5.
- 15 To stop such tissue degradation of skin and mucosal membranes, the present invention proposes to deplete mast cells using compounds that are substantially specific to mast cells. In this regard, tyrosine kinase inhibitors and more particularly c-kit specific kinase inhibitors are proposed to inhibit mast cell proliferation, survival and activation. Evidence of focal and complete degranulation of mast cells was observed in blisters or
- 20 bullae of patients affected with pemphigus. Besides, it is was observed that B lymphocyte clones produce antibodies directed to the basal membrane of the epidermis. Here, we propose that activation of such detrimental immune response to the self can result from degranulation of mast cells. In addition, this activation of components of immunity goes with the release of proteases that further contribute to the degradation of
- 25 tissues.

CLAIMS


- 5 1. A method for treating autoimmune diseases comprising administering a compound capable of depleting mast cells to a mammal in need of such treatment.
2. A method according to claim 1 for treating autoimmune diseases comprising administering a tyrosine kinase inhibitor to a mammal in need of such treatment.
- 10 3. A method according to claim 2, wherein said tyrosine kinase inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.
4. A method according to claim 2 for treating autoimmune diseases comprising
15 administering a c-kit inhibitor to a mammal in need of such treatment.
5. A method according to claim 4, wherein said c-kit inhibitor is a non-toxic, selective and potent c-kit inhibitor.
- 20 6. A method according to claim 5, wherein said inhibitor is selected from the group consisting of indolinones, pyrimidine derivatives, pyrrolopyrimidine derivatives, quinazoline derivatives, quinoxaline derivatives, pyrazoles derivatives, bis monocyclic, bicyclic or heterocyclic aryl compounds, vinylene-azaindole derivatives and pyridyl-quinolones derivatives, styryl compounds, styryl-substituted pyridyl compounds,
25 seleoindoles, selenides, tricyclic polyhydroxylic compounds and benzylphosphonic acid compounds.

7. A method according to claim 5, wherein said inhibitor is selected from the group consisting of:

- pyrimidine derivatives, more particularly N-phenyl-2-pyrimidine-amine derivatives.
- indolinone derivatives, more particularly pyrrol-substituted indolinones,
- 5 - monocyclic, bicyclic aryl and heteroaryl compounds,
- and quinazoline derivatives.

8. A method according to claim 5, wherein said inhibitor is selected from the group consisting of N-phenyl-2-pyrimidine-amine derivatives having the formula II :


10



Wherein R1, R2 and R3 are independently chosen from H, F, Cl, Br, I, a C1-C5 alkyl or a cyclic or heterocyclic group, especially a pyridyl group;

15 R4, R5 and R6 are independently chosen from H, F, Cl, Br, I, a C1-C5 alkyl, especially a methyl group;

and R7 is a phenyl group bearing at least one substituent, which in turn possesses at least one basic site, such as an amino function, preferably the following group :



20

9. A method according to claim 8, wherein said inhibitor is the 4-(4-méthylpipérazine-1-ylméthyl)-N-[4-méthyl-3-(4-pyridine-3-yl)pyrimidine-2 ylmino]phényl]-benzamide.

10. A method according to one of claims 4 to 9, wherein said c-kit inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.
- 5 11. A method according to one of claims 4 to 10, wherein said c-kit inhibitor is an inhibitor of activated c-kit.
12. A method according to claim 11, wherein said inhibitor is capable of inhibiting constitutively activated-mutant c-kit.
- 10 13. A method according to claim 11, wherein said activated c-kit inhibitor is capable of inhibiting SCF-activated c-kit.
14. A method for treating autoimmune diseases comprising administering to a mammal
15 in need of such treatment a compound that is a selective, potent and non toxic inhibitor of activated c-kit obtainable by a screening method which comprises :
- a) bringing into contact (i) activated c-kit and (ii) at least one compound to be tested; under conditions allowing the components (i) and (ii) to form a complex,
 - b) selecting compounds that inhibit activated c-kit,
 - 20 c) testing and selecting a subset of compounds identified in step b), which are unable to promote death of IL-3 dependent cells cultured in presence of IL-3.
15. A method according to claim 14, wherein the screening method further comprises the step consisting of testing and selecting a subset of compounds identified in step b) that
25 are inhibitors of mutant activated c-kit, which are also capable of inhibiting SCF-activated c-kit wild.

16. A method according to claim 14, wherein activated c-kit is SCF-activated c-kit wild in step a).

17. A method according to one of claims 14 to 17, wherein putative inhibitors are tested
5 at a concentration above 10 μ M in step a).

18. A method according to one of claims 14 to 18, wherein IL-3 is preferably present in the culture media of IL-3 dependent cells at a concentration comprised between 0.5 and 10 ng/ml, preferably between 1 to 5 ng/ml.

10

19. A method according to claim 18, wherein IL-3 dependent cells are selected from the group consisting of mast cells, transfected mast cells, BaF3 and IC-2.

20. A method according to one of claims 14 to 19, wherein the extent to which
15 component (ii) inhibits activated c-kit is measured *in vitro* or *in vivo*.

21. A method according to one of claims 14 to 20, further comprising the step consisting of testing and selecting compounds capable of inhibiting c-kit wild at concentration below 1 μ M.

20

22. A method according to claim 14 or 21, wherein the testing is performed *in vitro* or *in vivo*.

23. A method according to one of claims 14 to 22, wherein the inhibition of mutant-
25 activated c-kit and/or c-kit wild is measured using standard biochemical techniques such as immunoprecipitation and western blot.

24. A method according to one of claims 14 to 23, wherein the amount of c-kit phosphorylation is measured.

25. A method according to one of claims 14 to 24, wherein identified and selected
5 compounds are potent, selective and non-toxic c-kit wild inhibitors.

26. A method for treating autoimmune diseases comprising administering to a mammal in need of such treatment a c-kit inhibitor obtainable by a screening method comprising :
a) performing a proliferation assay with cells expressing a mutant c-kit (for example in
10 the transphosphorylase domain), which mutant is a permanent activated c-kit, with a plurality of test compounds to identify a subset of candidate compounds targeting activated c-kit, each having an $IC_{50} < 10 \mu M$, by measuring the extent of cell death,

b) performing a proliferation assay with cells expressing c-kit wild said subset of candidate compounds identified in step (a), said cells being IL-3 dependent cells cultured
15 in presence of IL-3, to identify a subset of candidate compounds targeting specifically c-kit,

c) performing a proliferation assay with cells expressing c-kit, with the subset of compounds identified in step b) and selecting a subset of candidate compounds targeting c-kit wild, each having an $IC_{50} < 10 \mu M$, preferably an $IC_{50} < 1 \mu M$, by measuring the
20 extent of cell death.

27. A method according to claim 26, wherein the extent of cell death is measured by 3H thymidine incorporation, the trypan blue exclusion method or flow cytometry with propidium iodide.
25

28. A method according to one of claims 1 to 27 for preventing and/or treating autoimmune diseases in human.

29. A method according to one of claims 1 to 27 for treating multiple sclerosis, psoriasis, subepidermal blistering disorders, intestine inflammatory disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis and polyarthritis, local and systemic scleroderma, systemic lupus erythematosus, discoid lupus erythematosus, cutaneous
5 lupus, dermatomyositis, polymyositis, Sjogren's syndrome, nodular panarteritis, autoimmune enteropathy, proliferative glomerulonephritis, active chronic hepatitis, chronic fatigue syndrome and Vasculitis.

30. A method according to one of claims 1 to 27 for treating graft-versus-host disease or
10 graft rejection in any organ transplantation including kidney, pancreas, liver, heart, lung, and bone marrow.

31. A method according to one of claims 1 to 27 for treating active chronic hepatitis and chronic fatigue syndrome.

15

32. A method according to one of claims 1 to 27 for treating Lupus erythematosus.

33. A method according to one of claims 1 to 27 for treating psoriasis and subepidermal blistering disorders including aphthous ulcers, and several bullous diseases such as
20 Pemphigus vulgaris, Pemphigus vegetans, Pemphigus foliaceus, and Pemphigus erythematosus, bullous pemphigoid and cicatricial pemphigoid.

34. A method according to one of claims 1 to 27 for treating rheumatoid arthritis and polyarthritis.

25

35. A method according to one of claims 1 to 27 for treating Dermatomyositis.

36. A method according to one of claims 1 to 27 for treating ulcerative colitis and Crohn's disease.

37. A method according to one of claims 1 to 27 for treating multiple sclerosis.

5

38. Use of a c-kit inhibitor to manufacture a medicament for treating autoimmune diseases.

39. A composition suitable for topical administration comprising a compound capable of
10 depleting mast cells, preferably a tyrosine kinase inhibitor, more particularly a c-kit inhibitor for the treatment of psoriasis, systemic lupus erythematosus, discoid lupus erythematosus, cutaneous lupus, local and systemic scleroderma, dermatomyositis and Vasculitis.

40. A composition suitable for oral administration comprising a compound capable of
15 depleting mast cells, preferably a tyrosine kinase inhibitor, more particularly a c-kit inhibitor for the treatment of multiple sclerosis, intestine inflammatory disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis and polyarthritis, myasthenia gravis, polymyositis, graft-versus-host disease, graft rejection, Graves disease,
20 Addison's disease, autoimmune uveoretinitis, autoimmune thyroiditis, primary biliary cirrhosis, Sjogren's syndrome, nodular panarteritis, autoimmune enteropathy, proliferative glomerulonephritis, active chronic hepatitis, chronic fatigue syndrome and Vasculitis.

41. A composition suitable for intravenous, intramuscular, intra-arterial, intramedullary,
25 intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, enteral, sublingual, or rectal administration comprising a compound capable of depleting mast

cells, preferably a tyrosine kinase inhibitor, more particularly a c-kit inhibitor for the treating of autoimmune diseases.

42. A product comprising at least one compound capable of depleting mast cells, such as
5 a tyrosine kinase inhibitors, more particularly a non-toxic, selective and potent c-kit inhibitor and at least one antibiotic, preferably selected from dapsone, azathioprine, erythromycin, propionylerythromycin, neomycin, gentomycin, tobramycin, and mechlocycline for simultaneous, separate or sequential use for the treatment of subepidermal blistering disorders, such as pemphigus.

SEQUENCE LISTING

<110> AB Science

<120> Use of tyrosine kinase inhibitors for treating autoimmune diseases

<130> 342884 NT

<150> US 60/341,273

<151> 2001-12-20

<150> US 60/301,405

<151> 2001-06-29

<150> US 60/301,409

<151> 2001-06-29

<150> US 60/301,410

<151> 2001-06-29

<160> 5

<170> PatentIn Ver. 2.1

<210> 1

<211> 976

<212> PRT

<213> Homo sapiens

<220>

<223> Human c-kit

<400> 1

Met	Arg	Gly	Ala	Arg	Gly	Ala	Trp	Asp	Phe	Leu	Cys	Val	Leu	Leu	Leu
1				5					10					15	

Leu	Leu	Arg	Val	Gln	Thr	Gly	Ser	Ser	Gln	Pro	Ser	Val	Ser	Pro	Gly
			20					25					30		

Glu	Pro	Ser	Pro	Pro	Ser	Ile	His	Pro	Gly	Lys	Ser	Asp	Leu	Ile	Val
		35					40					45			

Arg	Val	Gly	Asp	Glu	Ile	Arg	Leu	Leu	Cys	Thr	Asp	Pro	Gly	Phe	Val
		50				55					60				

Lys	Trp	Thr	Phe	Glu	Ile	Leu	Asp	Glu	Thr	Asn	Glu	Asn	Lys	Gln	Asn
65					70					75					80

Glu	Trp	Ile	Thr	Glu	Lys	Ala	Glu	Ala	Thr	Asn	Thr	Gly	Lys	Tyr	Thr
				85					90					95	

Cys	Thr	Asn	Lys	His	Gly	Leu	Ser	Asn	Ser	Ile	Tyr	Val	Phe	Val	Arg
			100					105					110		

Asp	Pro	Ala	Lys	Leu	Phe	Leu	Val	Asp	Arg	Ser	Leu	Tyr	Gly	Lys	Glu
		115					120					125			

Asp	Asn	Asp	Thr	Leu	Val	Arg	Cys	Pro	Leu	Thr	Asp	Pro	Glu	Val	Thr
		130				135					140				

Asn	Tyr	Ser	Leu	Lys	Gly	Cys	Gln	Gly	Lys	Pro	Leu	Pro	Lys	Asp	Leu
145					150					155					160

Arg	Phe	Ile	Pro	Asp	Pro	Lys	Ala	Gly	Ile	Met	Ile	Lys	Ser	Val	Lys
				165					170					175	

Arg Ala Tyr His Arg Leu Cys Leu His Cys Ser Val Asp Gln Glu Gly
 180 185 190
 Lys Ser Val Leu Ser Glu Lys Phe Ile Leu Lys Val Arg Pro Ala Phe
 195 200 205
 Lys Ala Val Pro Val Val Ser Val Ser Lys Ala Ser Tyr Leu Leu Arg
 210 215 220
 Glu Gly Glu Glu Phe Thr Val Thr Cys Thr Ile Lys Asp Val Ser Ser
 225 230 235 240
 Ser Val Tyr Ser Thr Trp Lys Arg Glu Asn Ser Gln Thr Lys Leu Gln
 245 250 255
 Glu Lys Tyr Asn Ser Trp His His Gly Asp Phe Asn Tyr Glu Arg Gln
 260 265 270
 Ala Thr Leu Thr Ile Ser Ser Ala Arg Val Asn Asp Ser Gly Val Phe
 275 280 285
 Met Cys Tyr Ala Asn Asn Thr Phe Gly Ser Ala Asn Val Thr Thr Thr
 290 295 300
 Leu Glu Val Val Asp Lys Gly Phe Ile Asn Ile Phe Pro Met Ile Asn
 305 310 315 320
 Thr Thr Val Phe Val Asn Asp Gly Glu Asn Val Asp Leu Ile Val Glu
 325 330 335
 Tyr Glu Ala Phe Pro Lys Pro Glu His Gln Gln Trp Ile Tyr Met Asn
 340 345 350
 Arg Thr Phe Thr Asp Lys Trp Glu Asp Tyr Pro Lys Ser Glu Asn Glu
 355 360 365
 Ser Asn Ile Arg Tyr Val Ser Glu Leu His Leu Thr Arg Leu Lys Gly
 370 375 380
 Thr Glu Gly Gly Thr Tyr Thr Phe Leu Val Ser Asn Ser Asp Val Asn
 385 390 395 400
 Ala Ala Ile Ala Phe Asn Val Tyr Val Asn Thr Lys Pro Glu Ile Leu
 405 410 415
 Thr Tyr Asp Arg Leu Val Asn Gly Met Leu Gln Cys Val Ala Ala Gly
 420 425 430
 Phe Pro Glu Pro Thr Ile Asp Trp Tyr Phe Cys Pro Gly Thr Glu Gln
 435 440 445
 Arg Cys Ser Ala Ser Val Leu Pro Val Asp Val Gln Thr Leu Asn Ser
 450 455 460
 Ser Gly Pro Pro Phe Gly Lys Leu Val Val Gln Ser Ser Ile Asp Ser
 465 470 475 480
 Ser Ala Phe Lys His Asn Gly Thr Val Glu Cys Lys Ala Tyr Asn Asp
 485 490 495
 Val Gly Lys Thr Ser Ala Tyr Phe Asn Phe Ala Phe Lys Gly Asn Asn
 500 505 510
 Lys Glu Gln Ile His Pro His Thr Leu Phe Thr Pro Leu Leu Ile Gly
 515 520 525

Phe Val Ile Val Ala Gly Met Met Cys Ile Ile Val Met Ile Leu Thr
 530 535 540
 Tyr Lys Tyr Leu Gln Lys Pro Met Tyr Glu Val Gln Trp Lys Val Val
 545 550 555 560
 Glu Glu Ile Asn Gly Asn Asn Tyr Val Tyr Ile Asp Pro Thr Gln Leu
 565 570 575
 Pro Tyr Asp His Lys Trp Glu Phe Pro Arg Asn Arg Leu Ser Phe Gly
 580 585 590
 Lys Thr Leu Gly Ala Gly Ala Phe Gly Lys Val Val Glu Ala Thr Ala
 595 600 605
 Tyr Gly Leu Ile Lys Ser Asp Ala Ala Met Thr Val Ala Val Lys Met
 610 615 620
 Leu Lys Pro Ser Ala His Leu Thr Glu Arg Glu Ala Leu Met Ser Glu
 625 630 635 640
 Leu Lys Val Leu Ser Tyr Leu Gly Asn His Met Asn Ile Val Asn Leu
 645 650 655
 Leu Gly Ala Cys Thr Ile Gly Gly Pro Thr Leu Val Ile Thr Glu Tyr
 660 665 670
 Cys Cys Tyr Gly Asp Leu Leu Asn Phe Leu Arg Arg Lys Arg Asp Ser
 675 680 685
 Phe Ile Cys Ser Lys Gln Glu Asp His Ala Glu Ala Ala Leu Tyr Lys
 690 695 700
 Asn Leu Leu His Ser Lys Glu Ser Ser Cys Ser Asp Ser Thr Asn Glu
 705 710 715 720
 Tyr Met Asp Met Lys Pro Gly Val Ser Tyr Val Val Pro Thr Lys Ala
 725 730 735
 Asp Lys Arg Arg Ser Val Arg Ile Gly Ser Tyr Ile Glu Arg Asp Val
 740 745 750
 Thr Pro Ala Ile Met Glu Asp Asp Glu Leu Ala Leu Asp Leu Glu Asp
 755 760 765
 Leu Leu Ser Phe Ser Tyr Gln Val Ala Lys Gly Met Ala Phe Leu Ala
 770 775 780
 Ser Lys Asn Cys Ile His Arg Asp Leu Ala Ala Arg Asn Ile Leu Leu
 785 790 795 800
 Thr His Gly Arg Ile Thr Lys Ile Cys Asp Phe Gly Leu Ala Arg Asp
 805 810 815
 Ile Lys Asn Asp Ser Asn Tyr Val Val Lys Gly Asn Ala Arg Leu Pro
 820 825 830
 Val Lys Trp Met Ala Pro Glu Ser Ile Phe Asn Cys Val Tyr Thr Phe
 835 840 845
 Glu Ser Asp Val Trp Ser Tyr Gly Ile Phe Leu Trp Glu Leu Phe Ser
 850 855 860
 Leu Gly Ser Ser Pro Tyr Pro Gly Met Pro Val Asp Ser Lys Phe Tyr
 865 870 875 880

Lys Met Ile Lys Glu Gly Phe Arg Met Leu Ser Pro Glu His Ala Pro
885 890 895
Ala Glu Met Tyr Asp Ile Met Lys Thr Cys Trp Asp Ala Asp Pro Leu
900 905 910
Lys Arg Pro Thr Phe Lys Gln Ile Val Gln Leu Ile Glu Lys Gln Ile
915 920 925
Ser Glu Ser Thr Asn His Ile Tyr Ser Asn Leu Ala Asn Cys Ser Pro
930 935 940
Asn Arg Gln Lys Pro Val Val Asp His Ser Val Arg Ile Asn Ser Val
945 950 955 960
Gly Ser Thr Ala Ser Ser Ser Gln Pro Leu Leu Val His Asp Asp Val
965 970 975

<210> 2
<211> 30
<212> DNA
<213> Homo sapiens

<220>
<223> Primer

<400> 2
aagaagagat ggtacctcga ggggtgaccc

30

<210> 3
<211> 33
<212> DNA
<213> Homo sapiens

<220>
<223> Primer

<400> 3
ctgcttcgcg gccgcgttaa ctcttctcaa cca

33

<210> 4
<211> 20
<212> DNA
<213> Homo sapiens

<220>
<223> Primer

<400> 4
agctcgttta gtgaaccgtc

20

<210> 5
<211> 20
<212> DNA
<213> Homo sapiens

<220>
<223> Primer

<400> 5
gtcagacaaa atgatgcaac

20

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
9 January 2003 (09.01.2003)

PCT

(10) International Publication Number
WO 2003/002109 A3

(51) International Patent Classification⁷: **A61K 31/404**,
31/505, 31/506, 31/519, 31/517, 31/498, 31/415, 31/4709,
31/015, 31/095, 31/66, 31/00, A61P 37/00, 37/06, 21/00,
17/00, 17/06, 29/00

(21) International Application Number:
PCT/IB2002/003302

(22) International Filing Date: 28 June 2002 (28.06.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/301,405 29 June 2001 (29.06.2001) US
60/301,410 29 June 2001 (29.06.2001) US
60/301,409 29 June 2001 (29.06.2001) US
60/341,273 20 December 2001 (20.12.2001) US

(71) Applicant (for all designated States except US): **AB SCI-
ENCE** [FR/FR]; 3, avenue Georges V, F-75008 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MOUSSY, Alain**
[FR/FR]; 22 bis, passage Dauphine, F-75006 Paris (FR).
KINET, Jean-Pierre [FR/US]; 2 Hunt Road, Lexington,
MA 02173 (US).

(74) Agents: **MARTIN, Jean-Jacques** et al.; Cabinet Regim-
beau, 20, rue de Chazelles, F-75847 Paris Cedex 17 (FR).

(81) Designated States (national): **AE, AG, AL, AM, AT, AU,**
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations **AE,**
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES,
FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG,
MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG,
UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS,
MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI,
CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report

(88) Date of publication of the international search report:
27 May 2004

(15) Information about Correction:

Previous Correction:

see PCT Gazette No. 18/2003 of 1 May 2003, Section II

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: **USE OF TYROSINE KINASE INHIBITORS FOR TREATING AUTOIMMUNE DISEASES**

(57) Abstract: The present invention relates to a method for treating autoimmune diseases, more particularly selected from the group consisting of multiple sclerosis, ulcerative colitis, Crohn's disease, rheumatoid arthritis and polyarthritis, scleroderma, lupus erythematosus, dermatomyositis, pemphigus, polymyositis, vasculitis, as well as graft-versus host diseases, comprising administering a compound capable of depleting mast cells to a mammal in need of such treatment. Such compounds can be chosen from tyrosine kinase inhibitors and more particularly non-toxic, selective and potent c-kit inhibitors. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 02/03302

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/404 A61K31/505 A61K31/506 A61K31/519 A61K31/517
A61K31/498 A61K31/415 A61K31/4709 A61K31/015 A61K31/095
A61K31/66 A61K31/00 A61P37/00 A61P37/06 A61P21/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

CHEM ABS Data, SCISEARCH, EMBASE, MEDLINE, BIOSIS, EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 65908 A (BROWN MATTHEW FRANK ; PFIZER PROD INC (US); BLUMENKOPF TODD ANDREW) 23 December 1999 (1999-12-23) page 1, line 7 - line 13 page 10, line 39 - page 12, line 7 page 22, line 9 - page 24, line 35 claims 1,7-12	1-3, 28-37, 39-42
X	WO 01 27081 A (HILBERG FRANK ; SPEVAK WALTER (AT); MEEL JACOBUS VAN (AT); TONTSCH) 19 April 2001 (2001-04-19) page 69, paragraph 3 - page 70, paragraph 1 page 227 - page 230 claims 1-8	1-3,28, 29,34, 39-42

	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the International filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the International filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the International search

16 December 2002

Date of mailing of the international search report

01.04.2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

van der Kooij, M

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB 02/03302

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61P17/00 A61P17/06 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01 45689 A (SUGEN INC ;LIPSON KEN (US); MCMAHON GERALD (US)) 28 June 2001 (2001-06-28) page 1, line 29 -page 2, line 11 page 4, line 16 - line 19 page 34, line 9 -page 40, line 26 claims 1-3	1-7, 10-13, 28-42
X	WO 99 21859 A (GLAXO GROUP LTD ;GLENNON KIMBERLY CAROLINE (US); PEEL MICHAEL ROBE) 6 May 1999 (1999-05-06) page 30, line 14 - line 25 page 31, line 31 -page 32, line 5 page 66, line 27 -page 72, line 6 claims 1-21,25,26,32,34,40	1-7, 10-13, 28-42

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"a" document member of the same patent family

Date of the actual completion of the international search

16 December 2002

Date of mailing of the international search report

01 04 2003

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

van der Kooij, M

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB 02/03302

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1-7, 10-13 and 28-37 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: **14-27**
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-7 (partially), 10-13 (partially), 28-42 (partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 14-27

Claims 14-27 encompass a genus of compounds defined only by their function wherein the relationship between the structural features of the members of the genus and said function have not been defined. In the absence of such a relationship either disclosed in the as-filed application or which would have been recognized based upon information readily available to one skilled in the art, the skilled artisan would not know how to make and use compounds that lack structural definition. The fact that one could have assayed a compound of interest using the claimed assays does not overcome this defect since one would have no knowledge beforehand as to whether or not any given compound (other than those that might be particularly disclosed in an application) would fall within the scope of what is claimed. It would require undue experimentation (be an undue burden) to randomly screen undefined compounds for the claimed activity. Therefore, no search has been performed for claims 14-27 and 28-37 as far as dependent from 14-27 under Article 5 PCT and Article 6 PCT.

Present claims 1-5, 10-13 and 28-42 relate to compounds defined by reference to a desirable characteristic or property, namely a "a compound capable of depleting mast cells" (claims 1, 28-37 and 39-42), "tyrosine kinase inhibiting activity" (claims 2, 3, 28-37, 39-42) or "a c-kit inhibiting activity" (claims 4, 5, 10-13 and 28-42) or "a tyrosine kinase inhibitor or c-kit inhibitor unable to promote death of IL-13 dependent cells cultured in presence of IL-13" (claims 3, 10, 28-37). The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to its pharmacological profile or a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Furthermore, present claims 6 and 7 relate to a large number of only partially defined compounds in terms of "indolinones" (claim 6) or "indolinone derivatives, more particularly pyrrol-substituted indolinones" (claim 7). In fact, the claims contain so many options that a lack of clarity and conciseness within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search over the whole scope of the claims impossible. Consequently, the search of the first invention has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the therapeutically active indolinone compounds described the patents US5792783, EP934931, US5834504, US5883116, US5883113, US5886020, W09640116 and W00038519 (as referred to on page 6 of the description) in relation to autoimmune diseases.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-7 (partially), 10-13 (partially),
28-42 (partially).

The use of indolinones and compositions thereof for treating autoimmune diseases.

2. Claims: 1-7 (partially), 8-9, 10-13 (partially),
28-42 (partially).

The use of pyrimidine derivatives and compositions thereof for treating autoimmune diseases.

3. Claims: 1-6 (partially), 10-13 (partially),
28-42 (partially).

The use of pyrrolopyrimidine derivatives and compositions thereof for treating autoimmune diseases.

4. Claims: 1-7 (partially), 10-13 (partially),
28-42 (partially).

The use of quinazoline derivatives and compositions thereof for treating autoimmune diseases.

5. Claims: 1-6 (partially), 10-13 (partially),
28-42 (partially).

The use of quinoxaline derivatives and compositions thereof for treating autoimmune diseases.

6. Claims: 1-6 (partially), 10-13 (partially),
28-42 (partially).

The use of pyrazole derivatives and compositions thereof for treating autoimmune diseases.

7. Claims: 1-7 (partially), 10-13 (partially),
28-42 (partially).

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

The use of bis monocyclic, bicyclic or heterocyclic aryl compounds and compositions thereof for treating autoimmune diseases.

8. Claims: 1-6 (partially), 10-13 (partially),
28-42 (partially).

The use of vinylene-azaindole derivatives and compositions thereof for treating autoimmune diseases.

9. Claims: 1-6 (partially), 10-13 (partially),
28-42 (partially).

The use of pyridylquinolone derivatives and compositions thereof for treating autoimmune diseases.

10. Claims: 1-6 (partially), 10-13 (partially),
28-42 (partially).

The use of styryl or styryl-substituted pyridyl compounds and compositions thereof for treating autoimmune diseases.

11. Claims: 1-6 (partially), 10-13 (partially),
28-42 (partially).

The use of seleoindoles and compositions thereof for treating autoimmune diseases.

12. Claims: 1-6 (partially), 10-13 (partially),
28-42 (partially).

The use of selenides and compositions thereof for treating autoimmune diseases.

13. Claims: 1-6 (partially), 10-13 (partially),
28-42 (partially).

The use of tricyclic polyhydroxylic compounds and compositions thereof for treating autoimmune diseases.

14. Claims: 1-6 (partially), 10-13 (partially),
28-42 (partially).

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

The use of benzylphosphonic acid compounds and compositions thereof for treating autoimmune diseases.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 02/03302

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>US 6 133 305 A (TANG PENG CHO ET AL) 17 October 2000 (2000-10-17)</p> <p>column 5, line 1 - line 8 claims 5-9,13,14,17</p> <p>---</p>	1-7, 10-13, 28-42
X	<p>DE 198 44 003 A (BOEHRINGER INGELHEIM PHARMA) 30 March 2000 (2000-03-30)</p> <p>page 2, line 1 - line 26 page 8, line 62 - line 68 claims 1-9</p> <p>---</p>	1-3, 28-37, 39-42
X	<p>DE 198 24 922 A (BOEHRINGER INGELHEIM PHARMA) 9 December 1999 (1999-12-09)</p> <p>page 2, line 4 - line 26 page 8, line 14 - line 25 claims 1-10</p> <p>---</p>	1-3, 28-37, 39-42
Y	<p>KRYSTAL G W ET AL: "INDOLINONE TYROSINE KINASE INHIBITORS BLOCK KIT ACTIVATION AND GROWTH OF SMALL CELL LUNG CANCER CELLS" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 61, no. 9, 1 May 2001 (2001-05-01), pages 3660-3668, XP001080106 ISSN: 0008-5472 the whole document</p> <p>---</p>	1-7, 10-13, 28-42
Y	<p>WO 98 41525 A (KNOLL AG ;CALDERWOOD DAVID JOHN (GB); JOHNSTON DAVID NORMAN (GB);) 24 September 1998 (1998-09-24) page 1, line 14 - line 17 page 19, line 8 - line 11 page 19, line 13 - line 27 claims 1-24,26,28,29</p> <p>---</p>	1-7, 10-13, 28-42
A	<p>MOHAMMADI M ET AL: "STRUCTURES OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR IN COMPLEX WITH INHIBITORS" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 276, no. 5314, 9 May 1997 (1997-05-09), pages 955-960, XP002065235 ISSN: 0036-8075 the whole document</p> <p>---</p>	1-7, 10-13, 28-42

-/--

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB 02/03302

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BEERS, M.H. ET.AL.: "The Merck Manual of Diagnosis and Therapy." 1999, MERCK RESEARCH LABORATORIES, NEW YORK, USA XP002224556 page 1061, column 1, paragraph 1 -page 1063, column 2, paragraph 3 -----	1-7, 10-13, 28-42
P,X	WO 01 60814 A (NEMATALLA ASAAD S ;LI XIAOYUAN (US); LIANG CONGXIN (US); MILLER TO) 23 August 2001 (2001-08-23) page 4, line 20 - line 28 page 9, line 26 - line 31 page 63, line 29 -page 74, line 13 page 74, line 16 -page 83, line 5 claims 1-55,58 -----	1-3, 28-37, 39-42

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 02/03302

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9965908	A	23-12-1999	AP 1021 A	09-11-2001
			AU 3951899 A	05-01-2000
			BG 105129 A	30-11-2001
			BR 9911365 A	13-03-2001
			CA 2335492 A1	23-12-1999
			CN 1305480 T	25-07-2001
			CZ 20004727 A3	13-03-2002
			EP 1087970 A1	04-04-2001
			HR 20000885 A1	31-10-2001
			HU 0102574 A2	28-11-2001
			WO 9965908 A1	23-12-1999
			JP 2002518393 T	25-06-2002
			NO 20006453 A	05-02-2001
			PL 345123 A1	03-12-2001
			SK 18982000 A3	06-08-2002
			TR 200003719 T2	21-03-2001
			US 2002019526 A1	14-02-2002
			ZA 9904004 A	18-12-2000
WO 0127081	A	19-04-2001	DE 19949208 A1	19-04-2001
			DE 10042696 A1	14-03-2002
			AU 1023301 A	23-04-2001
			BR 0014735 A	16-07-2002
			CN 1391557 T	15-01-2003
			CZ 20021410 A3	17-07-2002
			WO 0127081 A1	19-04-2001
			EP 1224170 A1	24-07-2002
			NO 20021719 A	11-04-2002
			SK 6462002 A3	06-08-2002
WO 0145689	A	28-06-2001	AU 3436301 A	03-07-2001
			EP 1255536 A2	13-11-2002
			WO 0145689 A2	28-06-2001
			US 2002010203 A1	24-01-2002
WO 9921859	A	06-05-1999	AU 1151099 A	17-05-1999
			WO 9921859 A1	06-05-1999
			ZA 9809249 A	10-04-2000
US 6133305	A	17-10-2000	US 2001007033 A1	05-07-2001
			US 2002026053 A1	28-02-2002
			AU 7661498 A	27-11-1998
			EP 0984930 A1	15-03-2000
			JP 2002511852 T	16-04-2002
			WO 9850356 A1	12-11-1998
DE 19844003	A	30-03-2000	DE 19844003 A1	30-03-2000
			AU 6086399 A	17-04-2000
			BG 105327 A	31-12-2001
			BR 9914065 A	19-06-2001
			CA 2342622 A1	06-04-2000
			CN 1319090 T	24-10-2001
			EE 200100184 A	15-08-2002
			WO 0018734 A1	06-04-2000
			EP 1115704 A1	18-07-2001
			HR 20010216 A1	30-04-2002
			HU 0104973 A2	29-04-2002
			JP 2002525356 T	13-08-2002

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 02/03302

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
DE 19844003	A		NO 20011477 A PL 346898 A1 SK 4032001 A3 TR 200100854 T2	22-03-2001 11-03-2002 06-11-2001 21-12-2001
DE 19824922	A	09-12-1999	DE 19824922 A1 AU 4370799 A BG 104938 A BR 9910898 A CA 2328291 A1 CN 1303374 T EE 200000723 A WO 9962882 A1 EP 1100779 A1 HR 20000831 A1 HU 0102210 A2 JP 2002516906 T NO 20006138 A PL 344467 A1 SK 18222000 A3 TR 200003515 T2 US 6319918 B1	09-12-1999 20-12-1999 29-06-2001 13-02-2001 09-12-1999 11-07-2001 15-04-2002 09-12-1999 23-05-2001 31-12-2001 28-11-2001 11-06-2002 01-02-2001 05-11-2001 06-08-2001 21-06-2001 20-11-2001
WO 9841525	A	24-09-1998	AU 748884 B2 AU 6829398 A BG 103785 A BR 9808281 A CN 1259950 T WO 9841525 A1 EP 0970084 A1 HU 0001507 A2 JP 2001516353 T NO 994509 A NZ 337529 A PL 335685 A1 SK 125999 A3 TR 9902301 T2 US 6001839 A	13-06-2002 12-10-1998 30-06-2000 16-05-2000 12-07-2000 24-09-1998 12-01-2000 28-10-2000 25-09-2001 17-09-1999 27-10-2000 08-05-2000 16-05-2000 21-12-1999 14-12-1999
WO 0160814	A	23-08-2001	AU 3977001 A EP 1255752 A2 NO 20023831 A WO 0160814 A2 US 2002156292 A1	27-08-2001 13-11-2002 15-10-2002 23-08-2001 24-10-2002

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 January 2003 (09.01.2003)

PCT

(10) International Publication Number
WO 03/002109 A2

(51) International Patent Classification⁷: A61K 31/00

(21) International Application Number: PCT/IB02/03302

(22) International Filing Date: 28 June 2002 (28.06.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/301,405 29 June 2001 (29.06.2001) US
60/301,410 29 June 2001 (29.06.2001) US
60/301,409 29 June 2001 (29.06.2001) US
60/341,273 20 December 2001 (20.12.2001) US

(71) Applicant (for all designated States except US): AB SCIENCE [FR/FR]; 3, avenue Georges V, F-75008 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MOUSSY, Alain [FR/FR]; 22 bis, passage Dauphine, F-75006 Paris (FR). KINET, Jean-Pierre [FR/US]; 2 Hunt Road, Lexington, MA 02173 (US).

(74) Agents: MARTIN, Jean-Jacques et al.; Cabinet Regimbeau, 20, rue de Chazelles, F-75847 Paris Cedex 17 (FR).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

Published:

- without international search report and to be republished upon receipt of that report

(48) Date of publication of this corrected version:

1 May 2003

(15) Information about Correction:

see PCT Gazette No. 18/2003 of 1 May 2003, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF TYROSINE KINASE INHIBITORS FOR TREATING AUTOIMMUNE DISEASES

(57) Abstract: The present invention relates to a method for treating autoimmune diseases, more particularly selected from the group consisting of multiple sclerosis, ulcerative colitis, Crohn's disease, rheumatoid arthritis and polyarthritis, scleroderma, lupus erythematosus, dermatomyositis, pemphigus, polymyositis, vasculitis, as well as graft-versus host diseases, comprising administering a compound capable of depleting mast cells to a mammal in need of such treatment. Such compounds can be chosen from tyrosine kinase inhibitors and more particularly non-toxic, selective and potent c-kit inhibitors. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

WO 03/002109 A2